Methods of use and nutritional compositions of Touchi Extract

• US 8,815,312 B2
• Filed: 05/24/2007
• Issued: 08/26/2014
• Est. Priority Date: 05/26/2006
• Status: Expired due to Fees

• Current Assignee: Nestec SA (Nestle SA)
• Original Assignee: Nestec SA (Nestle SA)
• Inventors: Falk, Anne, Roughead, Zamzam (Fariba), Miller, Kevin Burke, Jonnalagadda, Satya, Greenberg, Norman Alan, Kaspar, Kala Marie, Swanson, Julie
• Primary Examiner(s): Mi, Qiuwen
• Application Number:
  US12/300,426
• Publication Number:
  US 20090148545A1
• Time in Patent Office: 2,651 Days
• Field of Search: None
• US Class Current: 424/757
• CPC Class Codes: A23L 11/50 Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms removing undesirable substances A23L11/30; soy sauce A23L27/50
• CPC Class Codes: A23L 11/70 Germinated pulse products, e.g. from soy bean sprouts
• CPC Class Codes: A23L 33/135 Bacteria or derivatives thereof, e.g. probiotics
• CPC Class Codes: A23L 33/40 Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/32 having an effect on the health of the digestive tract
• CPC Class Codes: A23V 2200/3202 Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
• CPC Class Codes: A23V 2200/3204 Probiotics, living bacteria to be ingested for action in the digestive tract
• CPC Class Codes: A23V 2200/326 having effect on cardiovascular health
• CPC Class Codes: A23V 2200/328 having effect on glycaemic control and diabetes
• CPC Class Codes: A23V 2250/2116 Flavonoids, isoflavones
• CPC Class Codes: A23V 2250/5488 Soybean protein
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 35/741 Probiotics probiotic yeast, e.g. saccharomyces A61K36/06
• CPC Class Codes: A61K 35/745 Bifidobacteria
• CPC Class Codes: A61K 35/747 Lactobacilli, e.g. L. acidophilus or L. brevis
• CPC Class Codes: A61K 36/48 Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 1/10 : Laxatives
• CPC Class Codes: A61P 1/12 : Antidiarrhoeals
• CPC Class Codes: A61P 1/16 : for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 : for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 15/00 : Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 : for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 15/10 : for impotence
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 3/00 : Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/18 : for HIV
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Disclosed is a method and composition for nutritional compositions containing glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome/Syndrome X, COPD, malabsorption, Crohn'"'"'s disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

Claims

1. A composition comprising at least one α

-glucosidase inhibitor and at least one flavanol, wherein the α

-glucosidase inhibitor is Touchi extract and the flavanol is at least one of an epicatechin compound and a catechin compound originating from a source selected from the group consisting of cocoa, wine, and combinations thereof, the composition further comprising a probiotic selected from the group consisting of E. coli Nissle 1917, Lactobacillus johnsonii, Bifidobacterium breve, Saccharomyces boulardii, and combinations thereof.

2. The composition of claim 1 further comprising at least one prebiotic.

3. The composition of claim 2 wherein said prebiotic is selected from the group consisting of fructooligosaccharides, galactooligosaccharides, inulin, partially hydrolyzed guar gum, and combinations thereof.

8. A method of treatment of a patient that can benefit from the composition as claimed in any one of claims 1, 2, and 3.

9. The method as claimed in claim 8, further comprising at least one prebiotic.

10. The method as claimed in claim 9 wherein said prebiotic is at least one of fructooligosaccharides, galactooligosaccharides, inulin and partially hydrolyzed guar gum.

11. The method as claimed in claim 8 further comprising at least one probiotic.

12. The method of treatment of a patient that can benefit from as claimed in claim 11 wherein said probiotic is at least one L. reuteri, E. coli Nissle 1917, L. rhamnosus GG, L. casei, L. johnsonii, L. salivarius, bifidobacteria breve, B. bifidus, and sacchromyces boulardi.

13. The method of treatment as claimed in claim 8, further comprising at least one probiotic and at least one prebiotic.

14. The method as claimed in claim 13 wherein:

(a) said prebiotic is at least one of fructooligosaccharides, galactooligosaccharides, inulin and partially hydrolyzed guar gum; and

(b) said probiotic is at least one L. reuteri, E. coli Nissle 1917, L. rhamnosus GG, L. casei, L. johnsonii, L. salivarius, bifidobacteria breve, B. bifidus, and sacchromyces boulardi.

15. A method as claimed in claim 8, wherein said patient has at least one of the following:

Diabetes, increased insulin resistance, decreased insulin sensitivity, co-morbidities of diabetes, cardiovascular disease, coronary heart disease, could benefit from decreased lipoproteins, hyperinsulinemia, hyperlipidemia, has or at risk for fatty liver, obesity, abdominal obesity, would benefit from improve satiety, would benefit from delay gastric emptying, Metabolic Syndrome/Syndrome X, chronic obstructive pulmonary disease would benefit from improved structure and function of the intestine, malabsorption, intestinal inflammation in active inflammatory bowel disease, Crohn'"'"'s disease, diarrhea, constipation, gut atrophy due to transition from parenteral nutrition, gut atrophy due to radiation therapy, gut atrophy due to radiation therapy chemotherapy, irritable bowel syndrome, benefit from enhance athletic performance, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, is a Critical Care Patient, has a wound that is or needs assistance in healing, Polycystic Ovarian Syndrome (PCOS), Erectile Dysfunction or erectile dysfunction secondary to diabetes.

16. A method as claimed in claim 15 wherein said lipoproteins are at least one of triglycerides, very-low-density lipoprotein cholesterol and low-density lipoprotein cholesterol.

17. A method as claimed in claim 15 wherein said patient with hyperinsulinemia has at least one of:

pro-inflammatory state or prothrombotic state.

18. A method as claimed in claim 15 wherein said patient has malabsoption from at least one of:

cancer, chemo-therapy, radiation-therapy, total parenteral nutrition-related gut atrophy, acute illness-related gut dysfunction, being critically ill, septic, being burned, trauma, secondary to surgery, secondary to medicine, or acute pancreatitis.

19. A method as claimed in claim 15 wherein said patient has irritable bowel syndrome from at least one of:

post bowel resection, short bowel syndrome, ulcerative colitis, gastrointestinal cancers, intestinal inflammation, acute illness-related gut dysfunction, being ill, being septic, being burned, trauma, secondary to surgery, secondary to medicine, acute pancreatitis, intestinal inflammation, cancer, chemo-therapy, or radiation-therapy.

20. A method as claimed in claim 15 wherein said Critical Care patient can benefit from at least one of faster and stronger wound healing, fewer infections, and decreased complications.

21. A method as claimed in claim 15 wherein said patient has a wound that is or needs assistance in healing and can benefit from at least one of:

faster and stronger wound healing, fewer infections and decreased complications.

22. A method as claimed in claim 15 wherein said PCOS patient has infertility associated with the PCOS.

23. A method of administering to a patient a composition comprising administering the composition of any one of claims 1, 2 and 3.

24. A method of administering to a patient a composition as claimed in claim 23 wherein said patient is a mammal.

25. A method of administering to a patient a composition as claimed in claim 23 wherein said patient is a human.

4. A dietary regime comprising at least one α

-glucosidase inhibitor and at least one flavanol, wherein the α

-glucosidase inhibitor is Touchi extract and the flavanol is at least one of an epicatechin compound and a catechin compound originating from a source selected from the group consisting of cocoa, wine, and combinations thereof, the dietary regime further comprising a probiotic selected from the group consisting of E. coli Nissle 1917, Lactobacillus johnsonii, Bifidobacterium breve, Saccharomyces boulardii, and combinations thereof.

5. A kit comprising a dietary regime selected from the group consisting of a food, a beverage, and combinations thereof of claim 4.

6. The dietary regime of claim 4 further comprising at least one prebiotic.

7. The dietary regime of claim 6 wherein said prebiotic is selected from the group consisting of fructooligosaccharides, galactooligosaccharides, inulin, partially hydrolyzed guar gum, and combinations thereof.

26. A method of administering to a patient a dietary regime comprising administering the dietary regime of any one of claims 4, 6 and 7.

27. A method of administering to a patient a dietary regime as claimed in claim 26 wherein said patient is a mammal.

28. A method of administering to a patient a dietary regime as claimed in claim 26 wherein said patient is a human.

29. A method of administering to a patient a dietary regime as claimed in claim 26 wherein said dietary regime is a food or beverage or combination thereof.